Research Topics
Genomes and Genes | S ZeuzemSummaryAffiliation: Saarland University Country: Germany Publications
| Collaborators
|
Detail Information
Publications
[Individualised treatment of chronic hepatitis C]S Zeuzem
Klinik für Innere Medizin II mit den Schwerpunkten Gastroenterologie, Hepatologie, Endokrinologie, Diabetologie und Ernährungsmedizin, Universitatsklinikum des Saarlandes, 66 421 Homburg Saar
Internist (Berl) 47:S20, S22-5. 2006..A longer treatment duration of up to 72 weeks appears reasonable for HCV-1 infected patients with serum HCV RNA levels of 50-6,000 U/ml at week 12 of therapy...- Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activityS Zeuzem
Department of Internal Medicine, Saarland University Hospital, 66421 Homburg Saar, Germany
Aliment Pharmacol Ther 24:1133-49. 2006..These patients have historically remained untreated but substantial evidence indicates liver damage, progression of disease and impaired quality of life in some individuals... - Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levelsStefan Zeuzem
Saarland University Hospital, Homburg Saar, Germany
Gastroenterology 127:1724-32. 2004.... - International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis CStefan Zeuzem
Saarland University Hospital, Homburg Saar, Germany
J Hepatol 43:250-7. 2005..The aim of this study was to increase virologic response rates by individualized treatment according to the early virologic response... - [Treatment of hepatitis C--update 2005]N Forestier
, Hepatologie, Endokrinologie, ,
Dtsch Med Wochenschr 130:S215-6. 2005 - Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremiaStefan Zeuzem
Clinic of Internal Medicine II, Department of Medicine, Saarland University Hospital, Kirrbergerstrasse, 66421 Homburg Saar, Germany
J Hepatol 44:97-103. 2006..The aim of the present study was to investigate this schedule in the era of pegylated interferon-alpha plus ribavirin... - Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis CStefan Zeuzem
Klinik fur Innere Medizin II, Universitatskliniken des Saarlandes, 66421 Homburg Saar, Germany
J Hepatol 39:106-11. 2003..Sensitive molecular tests may permit earlier determination of sustained virologic response following the completion of therapy in end-of-treatment responders... - Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3Stefan Zeuzem
Department of Medicine, Saarland University Hospital, Homburg Saar, Germany
J Hepatol 40:993-9. 2004..The aim of the present study was to investigate this schedule for HCV-2/3 infected patients in the era of pegylated interferon-alpha plus ribavirin... - Pharmacokinetics of peginterferonsStefan Zeuzem
Department of Medicine, Division of Gastroenterology, Hepatology, and Endocrinology, Saarland University Hospital, Homburg Saar, Germany
Semin Liver Dis 23:23-8. 2003..However, it remains unknown whether these differences in the initial viral decline predict differences in the primary clinical endpoint, sustained virological response... - [Chronic hepatitis C: new perspectives in therapy]S Zeuzem
, Hepatologie, Endokrinologie, , , Homburg/Saar
Z Gastroenterol 42:363-4. 2004 - News in hepatitis C: Report from the 39th annual meeting of the European Association for the Study of the LiverStefan Zeuzem
Department of Internal Medicine II, Division of Gastroenterology, Hepatology and Endocrinology, Saarland University Hospital, Homburg/Saar, Germany
Antivir Ther 10:179-83. 2005 - Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?Stefan Zeuzem
Department of Internal Medicine II, Saarland University Hospital, Homburg Saar, Germany
Ann Intern Med 140:370-81. 2004..This article reviews the data on interferon-based therapies among patients with lower chances for sustained virologic response and discusses the potential of the new pegylated interferons... - [Difficult-to-treat patients with chronic hepatitis C]S Zeuzem
Klinik fur Innere Medizin II, Universitatsklinikum des Saarlandes, Homburg Saar
Praxis (Bern 1994) 95:1459-64. 2006..g. serotonine re-uptake inhibitors for depression, erythropoetin for ribavirin-associated anemia, etc.). In addition, optimisation of adherence and compliance is always mandatory... - [Combination therapy for chronic viral hepatitis C]S Zeuzem
, Hepatologie und Endokrinologie, , Homburg/Saar
Dtsch Med Wochenschr 128:370-4. 2003 - [Chronic hepatitis C virus infection: always treat!--Pro]S Zeuzem
, Hepatologie und Endokrinologie, , Germany
Dtsch Med Wochenschr 127:1840. 2002 - [Treatment of hepatitis B and C -- current standards]S Zeuzem
, Hepatologie, Endokrinologie, , , Homburg/Saar
Dtsch Med Wochenschr 129:S57-9. 2004 - [Treatment of hepatitis C virus infection]S Zeuzem
Klinik für Innere Medizin II mit den Schwerpunkten Gastroenterologie, Hepatologie und Endokrinologie, Universitatsklinikum des Saarlandes, Homburg, Saar
Praxis (Bern 1994) 94:721-6. 2005..Possibly, interferon-alpha also reduces the risk for patients with chronic hepatitis C to develop hepatocellular carcinoma... - First-phase parameters in hepatitis C viral kineticsStefan Zeuzem
Department of Medicine, Division of Gastroenterology, Hepatology, and Endocrinology, University Hospital Homburg/Saar, Germany
J Viral Hepat 9:332-3. 2002 - The American Association For the Study of Liver Diseases: new perspectives in the treatment of hepatitis CStefan Zeuzem
Saarland University Hospital, Homburg, Saar, Germany
Antivir Ther 11:267-71. 2006 - Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirinA Potthoff
Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany
Scand J Gastroenterol 44:1487-90. 2009..In contrast, a sustained response concerning HCV is durable. We recommend long-term monitoring of HBV/HCV-co-infected patients after IFN a-based therapies... - Correlation of amino acid variations within nonstructural 4B protein with initial viral kinetics during interferon-alpha-based therapy in HCV-1b-infected patientsM W Welker
Klinik fur Innere Medizin II, Universitatsklinikum des Saarlandes, Homburg Saar, Germany
J Viral Hepat 14:338-49. 2007..Amino acid variations with relevant changes of physicochemical properties may influence replication efficiency, associated with a rapid early virological response... - Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapyChristoph Sarrazin
Department of Internal Medicine, J W Goethe University Hospital, Frankfurt, Germany
J Hepatol 52:832-8. 2010..It is unknown whether shortening of treatment duration to 16/24 weeks in patients with rapid virological response at week 4 (RVR) and viral loads between 10 and 50IU/ml is possible... - The kinetics of hepatitis C virus infectionS Zeuzem
Department of Medicine, Division of Gastroenterology and Hepatology, University of Frankfurt a M, Germany
Clin Liver Dis 5:917-30. 2001..Nonresponding patients typically show constant viremia or even a rebound during this second phase... - Review article: predicting response in hepatitis C virus therapyU Mihm
Department of Internal Medicine II, Saarland University, Homburg/Saar, Germany
Aliment Pharmacol Ther 23:1043-54. 2006.... - SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonrespondersChristoph Sarrazin
Department of Internal Medicine II, Saarland University Hospital, Homburg, Germany
Gastroenterology 132:1270-8. 2007.... - [Postexposure prevention after occupational exposure to HBV, HCV and HIV]U Sarrazin
, , Homburg/Saar, Germany
Unfallchirurg 107:129-142. 2004..PEP should be started as early as possible and carried out for 28 days. The recommended PEP consists of two inhibitors of the reverse transcriptase and one inhibitor of the protease... - Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis CB Kronenberger
, , 66421 Homburg/Saar, Germany
J Viral Hepat 12:307-14. 2005.... - Somatic hypermutation and mRNA expression levels of the BCL-6 gene in patients with hepatitis C virus-associated lymphoproliferative diseasesW P Hofmann
Klinik fur Innere Medizin II, Kirrbergerstrasse, Universitatsklinikum des Saarlandes, Homburg, Germany
J Viral Hepat 14:484-91. 2007..005). Although HCV can induce BCL-6 mutations in vitro, lower mutational frequencies and decreased BCL-6 mRNA expression in vivo suggest no major role of aberrant somatic hypermutation in HCV-associated MC and B-NHL... - Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis CM Friedrich-Rust
Department of Internal Medicine, Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany
J Viral Hepat 16:168-77. 2009.... - Dynamics of hepatitis C virus infectionStefan Zeuzem
Department of Medicine, University Hospital Homburg/Saar, Germany
Ann Hepatol 1:56-63. 2002..This second phase decay is predictive for the virologic end-of-treatment and even more the sustained response. Non-responding patients typically show constant viremia or even a rebound during this second phase... - Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevirChristoph Sarrazin
Klinik fur Innere Medizin II, Universitat des Saarlandes, Homburg Saar, Germany
Gastroenterology 132:1767-77. 2007..4A protease inhibitor, has shown strong antiviral activity in phase 1 clinical studies. Because of high levels of HCV replication and the low fidelity of HCV polymerase, selection of resistant isolates during therapy may occur... - Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis CMarkus Cornberg
Department of Gastroenterology, Hepatology, and Endocrinology, Medizinische Hochschule Hannover, Carl Neuberg Strasse 1, D-30625 Hannover, Germany
J Hepatol 37:843-7. 2002..These data suggest that inhibition of the IMPDH seems not to be the major mechanism of ribavirin in enhancing the antiviral effect of interferon alfa in chronic hepatitis C... - Mutations in the putative HCV-E2 CD81 binding regions and correlation with cell surface CD81 expressionB Kronenberger
, , Homburg/Saar, Germany
J Viral Hepat 11:310-8. 2004.... - [Perspectives in hepatology in the next 2-3 years: what will be clinically relevant? Viral hepatitis]M Friedrich-Rust
, Hepatologie, Endokrinologie, ,
Dtsch Med Wochenschr 130:S229-30. 2005 - [Post-exposure prevention after occupational exposure to HBV, HCV and HIV]U Sarrazin
, , Homburg/Saar, Germany
Orthopade 33:231-44. 2004..PEP should be started as early as possible and carried out for 28 days. The recommended PEP consists of two inhibitors of the reverse transcriptase and one inhibitor of the protease... - Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levelsBernd Kronenberger
, , Homburg/Saar, Germany
Hepatology 40:1442-9. 2004..These data show that virological response in patients with chronic hepatitis C is less associated with baseline ALT than with GGT levels... - Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapyWolf Peter Hofmann
Department of Internal Medicine II, Saarland University Hospital, Homburg, Germany
Gastroenterology 132:921-30. 2007..Ribavirin acts as an RNA virus mutagen in vitro, thereby leading to error catastrophe. However, data in CHC are controversial... - Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis CMichael von Wagner
, Homburg/Saar, Germany
Gastroenterology 129:522-7. 2005..In patients infected by HCV-3 (high viral load), longer treatment may be necessary... - Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferonEva Herrmann
Medizinische Klinik und Poliklinik, Innere Medizin II, , Homburg/Saar, Germany
Hepatology 37:1351-8. 2003..This finding suggests that combination treatment leads to a better restoration of the patient's immune response... - Impaired health-related quality of life in patients with chronic hepatitis C and persistently normal aminotransferase levelsM von Wagner
, , Homburg, Saar, Germany
J Viral Hepat 13:828-34. 2006..No association of quality of life with severity of liver disease was found. Impairment of HRQOL by chronic infection with HCV is similar in patients with PNAL and those with elevated aminotransferase levels... - [Postexposure prophylaxis after occupational exposure to HBV, HCV and HIV]U Sarrazin
, , Homburg/Saar, Germany
Radiologe 44:181-94. 2004..PEP should be started as early as possible and carried out for 28 days. The recommended PEP consists of two inhibitors of the reverse transcriptase and one inhibitor of the protease... - Dynamics of hepatitis C virus quasispecies turnover during interferon-alpha treatmentM von Wagner
Innere Medizin II, , Homburg/Saar, Germany
J Viral Hepat 10:413-22. 2003..Thus, nonresponse to IFN cannot exclusively be explained by changes in the quasispecies... - Association of serum interleukin-8 with virologic response to antiviral therapy in patients with chronic hepatitis CUlrike Mihm
, , Kirrberger Strasse, D-66421 Homburg/Saar, Germany
J Hepatol 40:845-52. 2004..Thus, the conclusion from in vitro studies that the upregulation of interleukin-8 by the hepatitis C virus contributes to the inhibition of the antiviral actions of interferon-alpha may also be applicable in vivo... - GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infectionChristoph Sarrazin
Universitatsklinikum des Saarlandes, Klinik fur Innere Medizin II, Kirrberger Str 41, D 66421 Homburg Saar, Germany
J Hepatol 43:388-93. 2005..The G protein beta3 subunit (GNB3) C825T polymorphism has been shown to determine immune cell functions in vitro. We investigated the association of GNB3 genotypes with treatment response in HCV-infected patients... - Interleukin-18 is increased only in a minority of patients with active Crohn's diseaseC Schmidt
Department of Internal Medicine II, Saarland University, Homburg, Germany
Int J Colorectal Dis 22:1013-20. 2007..Therefore, we investigated the IL-18/IL-18 bp system in a large group of patients with active inflammatory bowel disease (IBD) to identify patients that could respond theoretically to IL-18 neutralizing treatment strategies... - Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapyC M Lange
Department of Medicine, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
Aliment Pharmacol Ther 32:14-28. 2010..Novel, directly acting anti-viral agents, also named 'specifically targeted anti-viral therapy for hepatitis C' (STAT-C) compounds, are currently under development... - Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis CNicole Forestier
Saarland University Hospital, Homburg, Germany
Hepatology 46:640-8. 2007..CONCLUSION: This study confirmed the substantial antiviral effects of telaprevir and showed an increased antiviral effect of telaprevir combined with peginterferon alfa-2a... - Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3.4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2aHuub C Gelderblom
Department of Gastroenterology and Hepatology, AMC Liver Center, Homburg Saar, Germany
Scand J Gastroenterol 43:1122-7. 2008..4A protease inhibitor telaprevir (VX-950), with or without peginterferon alfa-2a (Peg-IFN)... - Amino acid variations in hepatitis C virus p7 and sensitivity to antiviral combination therapy with amantadine in chronic hepatitis CUlrike Mihm
, , Kirrberger Str, 66421 Homburg/Saar, Germany
Antivir Ther 11:507-19. 2006..Non-responders with HCV-1b infection showed higher numbers of non-conservative aa variations within HCV p7 than responders, irrespective of the application of amantadine... - Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapyWolf Peter Hofmann
, , Homburg/Saar, Germany
J Clin Virol 32:86-91. 2005..For the NS5A protein, mutations within the interferon sensitivity determining region (ISDR) and the complete NS5A protein may be of importance for response to interferon alpha-based treatment in patients infected with HCV subtype 1a/b... - The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infectionAndrej Potthoff
Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany
J Hepatol 49:688-94. 2008..The efficacy of pegylated interferon alpha and ribavirin in HBV/HCV co-infected patients is unknown... - Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based studyI Blumenstein
First Department of Internal Medicine, Division of Gastroenterology, Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt Main, Germany
J Crohns Colitis 5:203-10. 2011..The aim of the present study was to evaluate gender-related differences in the treatment of a distinct IBD patient population treated in the Rhein-Main region, Germany... - Interferon-based therapy for chronic hepatitis C: current and future perspectivesStefan Zeuzem
Department of Medicine, JW Goethe University Hospital, Frankfurt, Germany
Nat Clin Pract Gastroenterol Hepatol 5:610-22. 2008..These compounds will be used, at least initially, in combination with peginterferon alpha plus ribavirin, extending the pivotal role of interferon-based therapy in the management of chronic hepatitis C... - Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061Eva Herrmann
Medizinische Klinik und Poliklinik, Innere Medizin II, Universitatsklinikum des Saarlandes, Homburg Saar, Germany
Antivir Ther 11:371-6. 2006..Estimates of viral clearance and infected-cell loss support conclusions on these rates and on treatment mechanisms from previous studies on interferon-alpha-based treatments... - Increased cytokine transcripts in pouchitis reflect the degree of inflammation but not the underlying entityC Schmidt
Department of Internal Medicine II, Saarland University Hospital, Homburg/Saar, Germany
Int J Colorectal Dis 21:419-26. 2006..Quantification of transcript levels allows an estimation of the extent of mucosal inflammation and may become helpful in the evaluation of the disease, especially in clinical trials... - [Standard treatment of acute and chronic hepatitis C]S Zeuzem
Medizinische Klinik und Poliklinik - Innere Medizin II, , Homburg
Z Gastroenterol 42:714-9. 2004 - [Generalized hyperpigmentation and malignant acanthosis nigricans. A case of a patient with hereditary hemochromatosis and gastric cancer]A Kalt
Klinik für Dermatologie Venerologie und Allergologie, Universitätsklinikum des Saarlandes Homburg Saar
Hautarzt 56:581-5. 2005..Simultaneous manifestation of hyperpigmentation as a result of hemochromatosis as well as malignant acanthosis nigricans as a paraneoplastic symptom in gastric cancer is very rare... - Downregulation of CD44v6 in colorectal carcinomas is associated with hypermethylation of the CD44 promoter regionA Stallmach
Department of Internal Medicine II, Saarland University, Homburg Saar, Germany
Exp Mol Pathol 74:262-6. 2003..05). These results demonstrated that methylation of the 5'CpG island of the CD44 gene is closely associated with decreased expression of CD44v6 in human colorectal carcinomas... - Mutations within the CD81-binding sites and hypervariable region 2 of the envelope 2 protein: correlation with treatment response in hepatitis C virus-infected patientsWolf Peter Hofmann
Innere Medizin II, Medizinische Klinik und Poliklinik, , Homburg, Germany
J Infect Dis 187:982-7. 2003..9; range, 1-5) or those who did not respond (2.8; range, 1-5) (P = .041). However, when the same analyses were based only on functionally nonconserved mutations, no significant differences were observed... - Cholecystokinin stimulates extracellular signal-regulated kinase through activation of the epidermal growth factor receptor, Yes, and protein kinase C. Signal amplification at the level of Raf by activation of protein kinase CepsilonAlbrecht Piiper
Department of Internal Medicine II, University of the Saarland, D 66421 Homburg Saar, Germany
J Biol Chem 278:7065-72. 2003.... - Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5Christoph Sarrazin
Klinik fur Innere Medizin II, Universitatsklinikum des Saarlandes, Kirrberger Str, D 66421 Homburg Saar, Germany
J Clin Microbiol 44:729-37. 2006..For the HPS/CTM assay, a significant underestimation of the HCV RNA concentrations of genotypes 2a/c, 3, 4, and 5 was observed. For the bDNA assay, a constant lower quantification of genotypes 1 to 3 was detected... - Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis CHeiner Wedemeyer
Department of Gastroenterology, Hepatology, and Endocrinology, Medical University of Hannover, Germany
Vaccine 27:5142-51. 2009..Optimized vaccine responses may enhance sustained virologic response rates obtained with standard treatment of chronic hepatitis C... - The kinetics of hepatitis C virusEva Herrmann
Saarland University, Faculty of Medicine, Internal Medicine II, Homburg Saar, Germany
Eur J Gastroenterol Hepatol 18:339-42. 2006..The main aims of analysing hepatitis C viral kinetics include the efficient comparison of different treatment regimens, prediction of virological response, and conclusions on antiviral mechanisms of therapy... - Protein kinase A mediates cAMP-induced tyrosine phosphorylation of the epidermal growth factor receptorAlbrecht Piiper
Department of Internal Medicine, University of Saarland, D 66421, Homburg Saar, Germany
Biochem Biophys Res Commun 301:848-54. 2003..While PKA may directly phosphorylate the EGFR on serine residues, PKA-induced tyrosine phosphorylation of the EGFR occurs by an indirect mechanism... - Tumor regression by combination antisense therapy against Plk1 and Bcl-2Robert Elez
Department of Internal Medicine, Johann Wolfgang Goethe University, Frankfurt, Germany
Oncogene 22:69-80. 2003..This study provides evidence that combined systemic administration of antisense ODNs against proliferation and pro- survival associated targets and in vivo electroporation of tumors represents a promising antitumor therapeutic approach... - Clinical significance of in vitro replication-enhancing mutations of the hepatitis C virus (HCV) replicon in patients with chronic HCV infectionChristoph Sarrazin
Klinik fur Innere Medizin II, Universitat des Saarlandes, Homburg Saar, Germany
J Infect Dis 192:1710-9. 2005..Mutations in nonstructural (NS) hepatitis C virus (HCV) proteins enhance replication in HCV-1a/b replicons. The prevalence of such mutations and their clinical significance in vivo are unknown... - Analysis of the human MutLalpha.MutSalpha complexGuido Plotz
University of the Saarland, Klinik fur Innere Medizin II, Homburg Saar, Germany
Biochem Biophys Res Commun 340:852-9. 2006..The described conditions likely capture an intermediate of the repair reaction which has bound ATP and ADP in the two nucleotide-binding sites of MutSalpha... - Current therapy for hepatitis CMireen Friedrich Rust
Department of Internal Medicine, Saarland University Hospital, Kirrbergerstr, Bldg 41, 66421 Homburg Saar, Germany
Int J Colorectal Dis 22:341-9. 2007..The duration of therapy depends on the HCV genotype with currently 48 weeks for genotype 1 and 24 weeks for genotypes 2 and 3... - Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analysesChristoph Sarrazin
Medizinische Klinik II, Johann Wolfgang Goethe Universitat, 60590 Frankfurt am Main, Germany
J Virol 76:11079-90. 2002..For improvement of mutational analysis, a refined specific functional data test procedure is proposed... - DNA mismatch repair and Lynch syndromeGuido Plotz
Klinik fur Innere Medizin II, Universitatsklinikum des Saarlandes, Kirrberger Strasse, Gebäude 41, D 66421 Homburg, Germany
J Mol Histol 37:271-83. 2006..We review the biochemistry of mismatch repair and also introduce the clinical, diagnostic and genetic aspects of Lynch syndrome... - Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapyUlrike Mihm
, , Kirrberger Str, 66421 Homburg/Saar, Germany
J Hepatol 43:217-24. 2005.... - Elevated plasma levels of N-terminal pro-brain natriuretic peptide in patients with chronic hepatitis C during interferon-based antiviral therapyJorg Bojunga
Internal Medicine II, Saarland University Hospital, Kirrberger Strasse, 66421 Homburg Saar, Germany
World J Gastroenterol 12:5875-7. 2006..To investigate plasma levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), an established marker of cardiac function, in patients with chronic hepatitis C during interferon-based antiviral therapy... - Pertussis toxin inhibits cholecystokinin- and epidermal growth factor-induced mitogen-activated protein kinase activation by disinhibition of the cAMP signaling pathway and inhibition of c-Raf-1A Piiper
Department of Internal Medicine, Johann Wolfgang Goethe University, Frankfurt, Germany
Mol Pharmacol 58:608-13. 2000.... - Epac activation converts cAMP from a proliferative into a differentiation signal in PC12 cellsSimone Kiermayer
Department of Internal Medicine, University of Saarland, D 66421 Homburg Saar, Germany
Mol Biol Cell 16:5639-48. 2005..Thus, the present study showed that the outcome of cAMP signaling can depend heavily on the set of cAMP effectors activated... - Comparison of transcription mediated amplification (TMA) and reverse transcription polymerase chain reaction (RT-PCR) for detection of hepatitis C virus RNA in liver tissueWolf Peter Hofmann
, , 66421 Homburg, Germany
J Clin Virol 32:289-93. 2005..019). CONCLUSION: Our results suggest that both the extraction and amplification step of the TMA-based assay contribute to the higher sensitivity compared with standard RT-PCR... - Mutations in the MutSalpha interaction interface of MLH1 can abolish DNA mismatch repairGuido Plotz
Klinik fur Innere Medizin II, Gebäude 41 Kirrberger Strasse, Universitat des Saarlandes, D 66421 Homburg Saar, Germany
Nucleic Acids Res 34:6574-86. 2006.... - Antioxidative treatment reverses imbalances of nitric oxide synthase isoform expression and attenuates tissue-cGMP activation in diabetic ratsJorg Bojunga
Innere Medizin II, Medizinische Klinik und Poliklinik, Saarland University, Homburg Saar, Germany
Biochem Biophys Res Commun 316:771-80. 2004..Furthermore, our data show that antioxidative treatment is capable of reversing changes in the NO-cGMP system and may therefore be an important therapeutic option for preventing vascular damage in diabetes mellitus... - The way forward in HCV treatment--finding the right pathMichael P Manns
Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Hannover, Germany
Nat Rev Drug Discov 6:991-1000. 2007..Here we review the specific challenges posed by HCV, and recent developments in the design of vaccines and novel antiviral agents... - Ultrasound evaluation of perihepatic lymph nodes during antiviral therapy with the protease inhibitor telaprevir (VX-950) in patients with chronic hepatitis C infectionMireen Friedrich Rust
Department of Internal Medicine, Saarland University Hospital, Homburg Saar, Germany
Ultrasound Med Biol 33:1362-7. 2007.... - BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumorsNikolaus Lubomierski
2nd Department of Internal Medicine, Saarland University Hospital, Homburg Saar, Germany
Cancer 104:952-61. 2005..These alterations were attributed to defective DNA mismatch repair, which underlies MSI. It was the objective of this study to clarify the role of BRAF in colorectal carcinoma with MSI... - RNAse A-like enzymes in serum inhibit the anti-neoplastic activity of siRNA targeting polo-like kinase 1Jorg Haupenthal
Department of Internal Medicine II, University of Saarland, Homburg, Saar, Germany
Int J Cancer 121:206-10. 2007..This loss of anti-neoplastic activity can be prevented by inhibition of their degradation by RNAse A-like enzymes. This may have important implications for the development of a human therapeutic application of siRNAs... - MUTYH hotspot mutations in unselected colonoscopy patientsM Casper
Department of Medicine II, Saarland University Medical Centre, Homburg, Germany Department of Medicine 1, Goethe University, Frankfurt am Main, Germany Department of Medicine III, Westpfalz Hospital, Kaiserslautern, Germany
Colorectal Dis 14:e238-44. 2012..Q338H may be at increased risk for mild polyposis or CRC. In addition, MUTYH should be assessed as a potential susceptibility gene for the development of colitis-associated CRC in future... - Involvement of the platelet-derived growth factor receptor in angiotensin II-induced activation of extracellular regulated kinases 1 and 2 in human mesangial cellsU F Mondorf
Department of Medicine, Division of Nephrology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590, Frankfurt am Main, Germany
FEBS Lett 472:129-32. 2000..In conclusion, our data show that Ang II-induced activation of mitogenic signalling cascade in human mesangial cells involves ligand-independent activation of the PDGFR, but not of the coexpressed EGFR... - Hepatitis C viral kinetic modelsE Herrmann
Department of Medicine, Saarland University Hospital, Germany
Cell Death Differ 10:S7-8. 2003 - Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitisKalliopi Zachou
Department of Gastroenterology, Hepatology and Endocrinology, Hanover Medical School, Hanover, Germany
Liver Int 30:430-7. 2010..ii) Biochemical parameters did not accurately indicate the stage and grade of liver disease in chronic HDV and thus liver biopsy seems to remain the major tool for the evaluation of delta hepatitis patients... - Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II studyJohannes Wiegand
Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover, Germany
Hepatology 43:250-6. 2006..The high number of dropouts underlines the importance of thorough patient selection and close monitoring during therapy. Thus, future studies should identify factors predicting spontaneous viral clearance to avoid unnecessary therapy... - Absence of the interstitial cell of Cajal network in mitochondrial neurogastrointestinal encephalomyopathyV Zimmer
Department of Internal Medicine II, Saarland University Hospital, Homburg, Germany
Neurogastroenterol Motil 21:627-31. 2009.... - Receptor tyrosine kinases are signaling intermediates of G protein-coupled receptorsA Piiper
Department of Internal Medicine II, University of Saarland, D 66421 Homburg Saar, Germany
Curr Pharm Des 10:3539-45. 2004..This review focuses on the mechanisms how GPCRs and intracellular messengers elicit transactivation of different RTKs and the resulting different biological responses... - Overview of commercial HBV assays systemsStefan Zeuzem
Department of Internal Medicine II, University Hospital, Homburg/Saar, Germany
Methods Mol Med 95:3-13. 2004 - Structural and functional comparison of the non-structural protein 4B in flaviviridaeChristoph Welsch
Internal Medicine II, Saarland University Hospital, Kirrberger Strasse, 66421 Homburg Saar, Germany
J Mol Graph Model 26:546-57. 2007..Important structural and functional properties of NS4B are predicted with implications for ER-stress response, altered gene expression and replication efficacy... - Dynamics of CD81 expression on lymphocyte subsets during interferon-alpha-based antiviral treatment of patients with chronic hepatitis CBernd Kronenberger
Klinik fur Innere Medizin II, Universitatsklinikum des Saarlandes, Kirrberger Strasse, D 66421 Homburg Saar, Germany
J Leukoc Biol 80:298-308. 2006..033). Lymphocyte subsets show different patterns of CD81 response before and during antiviral treatment, which are associated with administration of IFN-alpha and antiviral response... - Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitisCarsten Schmidt
Department of Internal Medicine II, Saarland University, Homburg, Germany
Inflamm Bowel Dis 11:16-23. 2005..Notably, increased expression of IL-23 and IL-27 transcripts in CD suggests a T helper 1-dominated immunologic function in this disease... - N-terminus of hMLH1 confers interaction of hMutLalpha and hMutLbeta with hMutSalphaGuido Plotz
2nd Department of Medicine, University of the Saarland, Kirrberger Strasse, D 66421 Homburg Saar, Germany
Nucleic Acids Res 31:3217-26. 2003..We also examined another human homologue of bacterial MutL, hMutLbeta (hMLH1-hPMS1). We show that hMutLbeta interacts as efficiently with hMutSalpha as hMutLalpha, and that it predominantly binds to hMutSalpha via hMLH1 as well... - Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapyPaolo Pugnale
Department of Pathology and Immunology, University of Geneva Medical Center, 1211 Geneva, Switzerland
J Hepatol 48:932-8. 2008..Analysis of hepatitis C virus (HCV) RNA kinetics in compartments other than plasma may help in understanding HCV replication and identifying clinically significant patterns of treatment response... - hMutSalpha forms an ATP-dependent complex with hMutLalpha and hMutLbeta on DNAGuido Plotz
Second Department of Medicine, Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Germany
Nucleic Acids Res 30:711-8. 2002..Purified hMutLalpha showed an intrinsic affinity for DNA, with a preference for single-stranded over double-stranded DNA... - Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)Samuel S Lee
Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1
J Hepatol 37:500-6. 2002..We evaluated the prognostic value of baseline factors and early viral RNA among patients treated with peginterferon alfa-2a (40KD)... - Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient dataCalogero Cammà
IBIM, Consiglio Nazionale delle Ricerche, Palermo, Italy
Hepatology 39:333-42. 2004..The beneficial effects of peginterferon on liver histology are closely related to virologic response... - Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis CStefan Zeuzem
JW Goethe University Hospital, Frankfurt, Germany
Hepatology 48:407-17. 2008..1 versus 4.3 days; P = 0.006). CONCLUSION: Alb-IFN administered q2wk or q4wk may offer comparable efficacy, with an improved dosing schedule, compared with PEG-IFNalpha-2a...